Our treatments reduce the barriers to those seeking medical treatment by providing highly effective and safe therapies targeting untreated symptoms and diseases.
Eila® is a 12-week program for the treatment of tobacco dependence. The DTx is currently undergoing clinical trial in Germany to provide an evidence-based, clinically validated, and personalized digital therapy to patients.
In collaboration with:
The comprehensive DTx will provide treatment for currently undertreated symptoms associated with PF, such as low mood and anxiety, improving the patient's quality of life.
In collaboration with: